Buradasınız

Anasayfa » Content

HEMODİYALİZ HASTALARINDA PLAZMA TOTAL HOMOSİSTEİN DÜZEYLERİ

PLASMA TOTAL HOMOCYSTEINE LEVELS IN HEMODIALYSIS PATIENTS

Journal Name:

  • Türk Nefroloji, Diyaliz ve Transplantasyon Dergisi

Publication Year:

  • 1998

Key Words:

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Homocysteine (Hey) is an independent risk factor for atherosclerosis. Since atherosclerotic cardiovascular events are the most frequent death causes in end stage renal disease patients, in the present study, plasma total Hey levels, their relationship with renal functions and nutritional status and the effect of hemodialysis on plasma total Hey levels were investigated in hemodialysis patients. In 16 hemodialysis patients, pre- and postdialysis plasma total Hey , serum urea, creatinine and albumin levels were determined. As an indicator of dialysis adequacy, URR (urea reduction rate) values of the patients were calculated. The control group was consisted of 16 healthy subjects and their plasma total Hey levels were also measured. Predialysis plasma total Hey levels of the patients were compared to those of the controls and to the postdialysis levels. Additionally, it was also investigated whether predialysis and postdialysis plasma total Hey levels of the patients had relationship with serum urea, creatinine, albumin levels and URR values. The both of pre- and postdialysis levels of plazma total homosistein were higher than those of controls. While pre- and postdialysis plazma total homosistein levels had no correlation with nutritional statues of the patients, they had significant correlation with URR values. In conclusion, hemodialysis patients have elevated plasma total Hey levels. Although there is a reduction in plasma total Hey levels after hemodialysis session, they do not return to the normal in postdialysis period.
Bookmark/Search this post with
Abstract (Original Language): 
Homosistein (Hey) ateroskleroz için bağımsız bir risk faktörüdür. Son dönem böbrek hastalarında aterosklerotik kardiyovasküler olaylar en sık ölüm nedeni olduğundan bu çalışma hemodiyaliz hastalarından oluşan bir grupta plazma Hey düzeylerinin durumunu belirlemek, böbrek fonksiyonları ile ilişkisini incelemek, beslenme durumu ile olan ilişkisini saptamak ve hemodiyalizin plazma Hey düzeyleri üzerine olan etkisini araştırmak amacıyla gerçekleştirildi. On altı hemodiyaliz hastasının diyaliz öncesi ve sonrası plazma total Hey, serum üre, kreatinin ve albümin değerleri belirlendi. Hemodiyaliz yeterliliğinin bir göstergesi olarak URR (urea reduction rate) değerleri belirlendi. Kontrol grubu 16 sağlıklı bireyden oluşturuldu ve plazma total Hey düzeyleri saptandı. Hastaların diyaliz öncesi ve sonrası plazma total Hey düzeyleri kontrollerinkilerle ve birbirleri ile kıyaslandı. Ayrıca hastaların diyaliz öncesi ve sonrası plazma total Hey düzeylerinin serum üre, kreatinin, albümin düzeyleri ve URR değerleri ile olan ilişkisi araştırıldı. Çalışma grubunun diyaliz öncesi ve sonrası plazma total Hey düzeylerinin kontrollerinkinden anlamlı olarak yüksek olduğu, beslenme durumu ile ilişkili olmadığı ancak URR ile anlamlı ilişkili olduğu belirlendi. Sonuç olarak hemodiyaliz hastaları yüksek plazma total Hcyin düzeylerine sahiptirler. Son dönem böbrek hastalarında hemodiyaliz tedavisi tek başına plazma Hey düzeylerinin normal değerlerine dönmesi için yeterli olamamaktadır.
FULL TEXT (PDF): 
PDF icon pdf_tndt_216.pdf
  • 3
132-136
  • Turkish

REFERENCES

References: 

1. US Renal Data System, USRDS 1995 Annual Data Report. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disease; April 1995
Rostand SG, Brunzell JD, Canon RO, Victor RG. Cardiovascular complications in renal failure. J Am Soc Nephrol 1991; 2: 1053-1062
Malinow MR, Leverson J, Giral P et al. Role of blood pressure, uric acid, and hemorheological parameters on plasma homocysteine concentration. Atherosclerosis 1995; 114:175-180.
Donner MG, Klein GK, Mathes PB et al. Plasma total
homocysteine levels in patients with early -onset coronary heart disease and a low cardiovascular risk
profile. Metabolism 1998; 47: 273-279.
Chauveau P, Chadefaux B, Coude M. Hyperhomocysteinemia, a risk factor for atherosclerosis in chronic uremic patients. Kidnet Int 1993; 43 Suppl
41;S72-S77
Wilcken DEL, Gupta VJ. Sulphur containing amino acids in chronic renal failure with particular reference to homocystein and cystein-homocysteine mixed
disulpfide. Eur J Clin Invest 1979; 9:301- 307.
Ueland PM, Refsum H. Plasma homocysteine, a risk factor for vascular disease: Plasma levels in health, disease and drug therapy. J Lab Clin Med 1989; 114: 473-501.
Zidek W. Homocysteine- A new arteriosclerotic risk factor in end-stage renal failure. Nephron 1997; 75:
249-250.
Wilcken DEL, Gupta VJ. Accumulation of sulphur containing amino acids including cysteine-homocysteine in patients on maintenance hemodialysis.
Clin Sci 1980; 58: 427-430.
Kang SS, Wong PWK, Bidani A, Milanez S: Plasma
protein-bound homocysteine in patients requiring chronic hemodialysis: Clin Sci 1983; 65: 335-336.
Smolin LA, Laidlaw SA, Kopple JD. Altered plasma free and protein-bound sulphur amino acid levels in patients undergoing maintenance hemodialysis. Am J
Clin Nutr 1987; 45:737-743.
Goldstein MB, Jindal KK, Levin A,Stingebauch B. The
adequacy of hemodialysis: Assessment and achievement. In Jacobson HR, Striker GE, Klahr S (eds)The principles and practice of Nephrology. Mosby,
St. Louisl995,pp 665-673.
Hultberg B, Andersson A , Sterner G. Plasma homocysteine in renal failure. Clin Nephrol 1993; 40:
230-234.
14. Robinson K, Gupta A, Dennis V et al. Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation 1996; 94: 2743¬2748.
15. Wu LL, Wu J, Hunt SC et al. Plasma homocysteine as a risk factor for early familial coronary artery disease.
Clin Chem 1994; 40: 552-561.
16. Lussier, Cacan S, Xhignesse M, Piolot A, et al. Plasma total homocysteine in healthy subjects: sex specific relation with biological traits. Am J Clin Nutr 1996; 64: 587-593.
17. Tonstad S. Correlates of plasma total homocysteine in patients with hyperlipidaemia. Eur J Clin Invest 1997;
27: 1025-1029.
18. Bostom AG ,Brosnan JT , Hall B. Net uptake of plasma homocysteine by the rat kidney in vivo. Atherosclerosis
1995;116:59-62.
19. Guttormsen AB , Svarstad E, Ueland DM, Elimination of homocysteine from plasma in subjects with end -stage renal failure. Ir J Med Sci 1995 : 164 (suppll5): 8-9 (Abstract)
20. Bergstrom J, Alverstrand A, Furst P. Plasma and muscle free aminoacids in maintenance hemodialysis patients without protein malnutration. Kidney Int 1990; 38: 108¬114.
21. Tizianello A, Deferrari G, Garibotto G et al. Renal metabolism of amino acids and ammonium in subjects with normal renal function and in patients with chronic renal insufficiency. J Clin Invest 1980; 65: 1162-1173.
22. Arnadottir M, Brattström L, Simonsen O et al. The effect of high dose pyridoxine and folic acid supplementation on serum lipid and plasma homocysteine concentrations in dialysis patients. Clin
Nephrol 1993;40:236-240.
23. Fodinger M, Mannhalter C, Wolfl G et al. Mutation
(677 C to T) in the methylenetetrahydrofolate reductase gene aggravates hyperhomocysteinemia in hemodialysis patients. Kidney Int 1997; 52: 517-523.
24. Suliman ME, Anderstam B,Lindholm B, Bergstrom J. Total, free,and protein bound sulphur amino acids in uraemic patients. Nephrol Dial Transplant 1997; 12:
2332-2338.
136

Thank you for copying data from http://www.arastirmax.com